ArticleInfection and drug resistance2023
Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas.
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Antibacterial potential of antidepressants against extended-spectrum β-lactamase-producing Escherichia coli.Folia microbiologica · 2025Article
- Detection of a genetically related carbapenemase-producing Escherichia coli ST167 in clinical and environmental isolates: Evidence for clonal spread of carbapenemase-producing Enterobacteriaceae in humans and the environment in Iowa, United States.Journal of global antimicrobial resistance · 2025Article
- Preliminary survey of biofilm forming, antibiotic resistant Escherichia coli in fishes from land based aquaculture systems and open water bodies in Bangladesh.Scientific reports · 2025Article
- Prevalence and antibiotic resistance of Escherichia coli in urban and peri-urban garden ecosystems in Bangladesh.PloS one · 2025Article
- Molecular Characterization of Multidrug-ResistantVeterinary sciences · 2024Article
- Identification of a novel CG307 sub-clade in third-generation-cephalosporin-resistantMicrobial genomics · 2024Article
- Risk Factors for 30-Day Mortality in Patients with Bacteremic Pneumonia Caused byInternational journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Carbapenem-resistant Enterobacterales (CRE) are subject to intense global monitoring in an attempt to maintain awareness of prevalent and emerging resistance mechanisms and to inform treatment and infection prevention strategies. CRE and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales are not usually examined collectively in regards to their shared pool of resistance determinants. Here, we genetically and phenotypically assess clinical isolates of CRE and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales in the growing region of Central Texas, where CRE are emergent and occurrence of non-carbapenemase-producing-CRE (non-CP-CRE) infections is increasing. Methods: CRE (n=16) and ESBL-producing Enterobacterales (n=116) isolates were acquired from a regional hospital in Central Texas between December 2018 and January 2020. Isolates were assessed genetically and phenotypically using antibiotic susceptibility testing, targeted PCR, and whole genome sequencing. Results: CRE infections are increasing in incidence in Central Texas, and Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.